| Kaoko Metals Limited (KAO) ORDINARY FULLY PAID |
Materials |
$14 |
Kaoko Investor & Shareholder Webinar Presentation
|
20 May 2026 9:27AM |
$0.450 |
$0.405 |
fallen by
10%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$10 |
Prospectus Bonus Issue and Target Market Determination
|
20 May 2026 9:26AM |
$0.001 |
$0.002 |
risen by
100%
|
|
1TT - Price-sensitive ASX Announcement
Full Release
Key Points
- Thrive Tribe Technologies Limited is offering a pro-rata non-renounceable entitlement issue of Loyalty Options.
- Eligible Shareholders will receive one Loyalty Option for every fifteen Shares they hold.
- Loyalty Options are exercisable at A$0.003 each and expire on 15 June 2029.
- The Record Date for determining Eligible Shareholders is 26 May 2026.
- The Offer is detailed in a Prospectus issued under section 713 of the Corporations Act.
- The Target Market Determination outlines distribution conditions and reporting requirements for the Loyalty Options.
- No funds will be raised from the Offer as Loyalty Options are issued for nil consideration.
- There is no cooling-off period for the issue of the Loyalty Options.
- The Offer is not underwritten, and no application forms are attached to the Prospectus.
- The Company’s directors have outlined their interests in the Company’s securities in the Prospectus.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MB Gold Limited (MBG) ORDINARY FULLY PAID |
Materials |
$8 |
Exceptional initial assay results from Twin Veins
|
20 May 2026 9:25AM |
$0.190 |
$0.165 |
fallen by
13.16%
|
|
MBG - Price-sensitive ASX Announcement
Full Release
Key Points
- Exceptional initial assay results from Twin Veins Prospect.
- Significant gold intercept of 20m @ 1.74g/t Au from 81m.
- Ongoing drilling with further results expected in three weeks.
- Phase 2 drill program to commence in August.
- MB Gold's Marble Bar Gold Project shows high potential.
- Project location offers excellent infrastructure and accessibility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cleo Diagnostics Ltd (COV) ORDINARY FULLY PAID |
Health Care |
$65 |
CLEO Establishes U.S. Reimbursement Pathway
|
20 May 2026 9:25AM |
$0.635 |
$0.475 |
fallen by
25.20%
|
|
COV - Price-sensitive ASX Announcement
Full Release
Key Points
- CLEO establishes U.S. reimbursement pathway using CPT code 81599.
- Immediate market entry and revenue generation post-FDA clearance.
- Reimbursement levels for comparable tests range from ~US$500–$900 per test.
- The pathway allows early prescribing and clinical use in U.S. healthcare settings.
- CLEO plans to apply for a dedicated CPT code to enhance reimbursement consistency.
- The strategy includes generating real-world evidence to support future CPT applications.
- CLEO's plan involves health economics and budget impact model development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Contact Energy Limited (CEN) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$8,222 |
Trading Halt
|
20 May 2026 9:24AM |
$8.200 |
$7.680 |
fallen by
6.34%
|
|
CEN - Price-sensitive ASX Announcement
Full Release
Key Points
- Contact Energy Limited requested a trading halt on 20 May 2026.
- The halt was due to a sale process initiated by Infratil Investments Limited.
- The sale involved a fully underwritten block trade of shares.
- Halt aimed to prevent market distortion and ensure orderly off-market sale.
- Trading expected to resume by market open on 22 May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$401 |
Update - Notification of buy-back - RG8
|
20 May 2026 9:24AM |
$2.820 |
$2.800 |
fallen by
0.71%
|
|
| GWA Group Limited (GWA) ORDINARY FULLY PAID |
Industrials |
$591 |
Update - Notification of buy-back - GWA
|
20 May 2026 9:23AM |
$2.050 |
$2.230 |
risen by
8.78%
|
|
| Black Bear Minerals Limited (BKB) ORDINARY FULLY PAID |
Materials |
$81 |
Investor Presentation - Canaccord Metals & Mining Conference
|
20 May 2026 9:23AM |
$0.700 |
$0.530 |
fallen by
24.29%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$577 |
Update - Notification of buy-back - RG1
|
20 May 2026 9:23AM |
$2.260 |
$2.440 |
risen by
7.96%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$6 |
Hydrix positioned for Defence tech expansion
|
20 May 2026 9:23AM |
$0.013 |
$0.004 |
fallen by
69.23%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix has entered a binding contract with NIOA Group to develop counter-Uncrewed Aerial Systems (C-UAS) for Defence applications.
- The contract supports the expansion of Hydrix's expertise in mission-critical embedded electronics and systems integration.
- Hydrix has launched an $8.18 million Entitlement Offer to raise funds for debt reduction and working capital, with a focus on Defence tech growth.
- Commitments have been made to convert $5.113 million of convertible note debt into equity.
- The global counter-UAS market is projected to grow at a CAGR of ~25%, reaching USD $20.3 billion by 2030.
- Hydrix plans to leverage its core engineering capabilities from the MedTech sector to expand its Defence technology offerings.
- Hydrix's strategy includes developing sovereign counter-drone capabilities in response to national Defence needs.
- Hydrix is focused on expanding its presence in Defence technology and pursuing opportunities in embedded intelligence and autonomy-enabling technologies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$675 |
Future Generation Global Board of Directors Update
|
20 May 2026 9:22AM |
$1.650 |
$1.680 |
risen by
1.82%
|
|
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$6 |
Hydrix raises $3.89m under Institutional Entitlement Offer
|
20 May 2026 9:22AM |
$0.013 |
$0.004 |
fallen by
69.23%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited completed the institutional component of its $8.183 million pro-rata accelerated renounceable entitlement offer.
- The Institutional Entitlement Offer raised approximately $3.89 million at an offer price of $0.005 per share.
- Institutional shareholders did not take up their entitlements, which were sold in the institutional shortfall bookbuild process.
- New institutional investors and family offices subscribed for all available shares under the bookbuild, raising $3,887,349 before offer costs.
- Hydrix's shares are expected to resume normal trading on the ASX on an ex-entitlement basis.
- The Retail Entitlement Offer aims to raise an additional $4.3 million, allowing eligible retail shareholders to subscribe for new shares at the same offer price.
- The proceeds will be used to retire and pay down debt, cover offer costs, and provide working capital for ongoing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Iceni Gold Limited (ICL) ORDINARY FULLY PAID |
Materials |
$9 |
Exploration Update - Advancing Multiple Targets
|
20 May 2026 9:22AM |
$0.022 |
$0.022 |
fallen by
0%
|
|
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$29 |
Noxopharms Sofra assets to be presented at global conference
|
20 May 2026 9:21AM |
$0.064 |
$0.093 |
risen by
45.31%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm’s Sofra assets will be presented at a global conference.
- The presentation will be by CSL at the Options for the Control of Influenza XIII Conference.
- Focus on improving delivery of self-amplifying mRNA vaccines.
- Sofra is a novel class of drugs targeting immune-related diseases.
- Potential applications include rheumatoid arthritis, lupus, diabetes, and oncology.
- Sofra’s versatility and immune system understanding are attracting industry attention.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Simble Solutions Limited (SIS) ORDINARY FULLY PAID |
Information Technology |
$16 |
Director Appointment
|
20 May 2026 9:21AM |
$0.006 |
$0.007 |
risen by
16.67%
|
|
| ImExHS Limited (IME) ORDINARY FULLY PAID |
Health Care |
$17 |
AGM - Chairman and CEO Addresses and Presentation
|
20 May 2026 9:20AM |
$0.350 |
$0.320 |
fallen by
8.57%
|
|
IME - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue of $29 million for FY25, up 10% year-on-year.
- Underlying EBITDA of $1.6 million, meeting the top end of guidance.
- Development of Aquila+, an AI platform automating the full radiology workflow.
- Appointment of new CTO and Sales Director to strengthen leadership.
- Continued expansion into the Mexican market, supported by channel partners.
- Approval of CEO option grants and additional share placement capacities.
- Positive outlook for FY26 with expectations to exceed FY25 EBITDA.
- Focus on market expansion, technology development, and financial discipline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Many Peaks Minerals Limited (MPK) ORDINARY FULLY PAID |
Materials |
$133 |
Trading Halt
|
20 May 2026 9:19AM |
$0.930 |
$0.795 |
fallen by
14.52%
|
|
MPK - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Many Peaks Minerals Limited (MPK).
- The halt is pending an announcement regarding a proposed capital raising.
- Trading halt to remain in place until 22 May 2026 or upon the announcement release.
- Request made under ASX Listing Rule 17.1.
- The company is managing its continuous disclosure obligations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$171 |
Purchasing Agreement Secured with CHRISTUS Health
|
20 May 2026 9:19AM |
$0.505 |
$0.380 |
fallen by
24.75%
|
|
EBR - Price-sensitive ASX Announcement
Full Release
Key Points
- EBR secured a three-year purchasing agreement with CHRISTUS Health.
- CHRISTUS Health is the ninth-largest hospital network in the U.S.
- The agreement covers the WiSE CRT System across 66 hospitals.
- The deal supports EBR's ongoing U.S. commercial rollout.
- CHRISTUS Health's network is primarily located in Texas, Louisiana, and New Mexico.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| KGL Resources Limited (KGL) ORDINARY FULLY PAID |
Materials |
$206 |
Corporate Presentation
|
20 May 2026 9:19AM |
$0.288 |
$0.268 |
fallen by
6.96%
|
|
| Oncosil Medical Limited (OSL) ORDINARY FULLY PAID |
Health Care |
$18 |
OncoSil Medical Receives TGA Approval in Australia
|
20 May 2026 9:17AM |
$0.390 |
$0.585 |
risen by
50%
|
|
OSL - Price-sensitive ASX Announcement
Full Release
Key Points
- TGA approval received for OncoSil™ device for pancreatic cancer treatment in Australia.
- First Class III medical device approved targeting pancreatic tumors in Australia.
- Enables commercialization and broader market adoption in Australia.
- Strengthens global commercialization strategy for OncoSil Medical.
- Provides a new treatment option for approximately 4,353 new pancreatic cancer patients annually in Australia.
- Highlights Australia's leadership in oncology innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,194 |
Proposed issue of securities - GNP
|
20 May 2026 9:16AM |
$9.740 |
$10.800 |
risen by
10.88%
|
|
| Metgasco Limited (MEL) ORDINARY FULLY PAID |
Energy |
$1 |
Debt Bridging Facility
|
20 May 2026 9:16AM |
$0.016 |
$0.014 |
fallen by
12.50%
|
|
MEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Metgasco Limited accepts A$500,000 bridging loan facility.
- Loan provided by Glennon Small Companies Limited.
- Interest rate set at 10% per annum.
- Purpose is to meet short-term capital and working capital requirements.
- Restructuring of Metgasco's debt stack is a condition of the loan.
- Announcement authorized by Metgasco's Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$82 |
US Media Tech Leader Joins ION Advisory Board
|
20 May 2026 9:16AM |
$0.360 |
$0.620 |
risen by
72.22%
|
|
IOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Kelli Richards joins ION Video's Advisory Board.
- The Advisory Board is non-governance and aims to support strategic guidance.
- Richards brings extensive industry experience from the tech and media sectors.
- Advisory Board will aid in the company's commercialization strategy.
- Richards to receive equity incentives as part of her role.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,194 |
A$200M Placement for Acquisition of MPC Kinetic
|
20 May 2026 9:16AM |
$9.740 |
$10.800 |
risen by
10.88%
|
|
GNP - Price-sensitive ASX Announcement
Full Release
Key Points
- A$200 million placement for MPC Kinetic acquisition
- Placement at A$9.25 per New Share
- 5.0% discount to last closing price
- Bell Potter and Euroz Hartleys as Joint Lead Managers
- Completion of acquisition expected by 1 July 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GenusPlus Group Ltd (GNP) ORDINARY FULLY PAID |
Industrials |
$2,194 |
Presentation- Acquisition of MPC Kinetic and Capital Raising
|
20 May 2026 9:16AM |
$9.740 |
$10.800 |
risen by
10.88%
|
|
Call 1300 880 160
Start a chat
Schedule a call
